AutoAdapt produced acceptable prostate MR-guided plans with minimal planner input
AI-generated constraints produced clinically acceptable adaptive prostate plans, although only seven of ten met every prespecified planning objective.
AI-generated constraints produced clinically acceptable adaptive prostate plans, although only seven of ten met every prespecified planning objective.
MRI-defined biopsy-confirmed lesions can be boosted safely when robust image guidance and normal-tissue constraints take priority over complete boost coverage.
ESTRO recommends prostate SBRT for selected intermediate-risk disease with MRI-based contouring, rigorous quality assurance, and daily image guidance.
Linac-based 40 Gy in five fractions produced low severe toxicity and rapid urinary recovery across seven centres, although follow-up remained short.
Millimeter-scale localization uncertainty shifted assigned biopsy doses by several Gy and made nominal DVH threshold classification frequently unreliable.
Perioperative apalutamide improved pathological response and composite MFS, but not conventional imaging-defined MFS, raising concern about overtreatment in broadly defined high-risk disease.
Extending first-generation antiandrogen therapy beyond short-term use was not associated with better survival and may increase early ADT discontinuation.
Five-fraction prostate radiotherapy achieved 82% three-year biochemical control with very few grade 3 toxicities in men aged 75 or older.
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.
Hydrogel spacer placement was associated with a 74% lower risk of gastrointestinal endoscopic hemostasis after prostate radiotherapy.
Daily adaptation increased prostate-bed coverage from 92.1% to 98.5% and reduced high-dose rectal exposure during hypofractionated salvage radiotherapy.
Five-fraction prostate radiotherapy produced 58.6% lower estimated carbon emissions than a 26-fraction schedule, mainly by reducing patient travel.
High-dose-rate brachytherapy using 13.5 Gy twice achieved 81.6% ten-year biochemical control with limited late genitourinary toxicity.
SFUD and robust IMPT maintained target coverage under uncertainty, while IMPT modestly reduced rectal and bladder dose.
Prospective prostate reirradiation studies reported generally acceptable toxicity, but target volumes, dose schedules and organ constraints varied substantially.